Effects of pemafibrate on saccharometabolism in patients with hypertriglyceridemia complicated with borderline diabetes or early diabetes

Osamu Tomonaga0 个研究点目标入组 20 人开始时间: 2019年11月22日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Fasting triglycerides over 150mg/dL and less than 500 mg / dL, or casual triglycerides over 200 mg / dL and less than 500 mg / dL (values for 12 weeks prior participation can be adopted)
•2. Agreed to receive 75g OGTT
•3. Aged 20-85 on day of signing informed consent
•4. Patients who have received sufficient explanation for participation in this study, and who have fully understood the study plan and consented to the document by their own will

•1. Currently receiving or are planning to receive diabetes agents
•2. Treated with fibrate agents within 12 weeks prior to the study
•3. Patients who have changed prescriptions for antihypertensive and dyslipidemia agents (including rotriga and epadale) within 12 weeks prior to the study
•4. Patients who fall under a contraindication listed in the pemafibrate package insert
•5. Patients with a history of malignant tumor or patients who are likely to relapse after remission
•6. Patients who are determined to be inappropriate for this study by the principal investigator or research investigator

发起方

Osamu Tomonaga